RAF1 as a standalone therapeutic target in KRAS-driven lung adenocarcinoma: No added efficacy from co-targeting ARAF, EGFR, or DDR1

• Laura de-la-Puente-Ovejero ,

  Contributed equally to this work with: Laura de-la-Puente-Ovejero, Ana Fernández-Rodríguez

  Roles Data curation, Formal analysis, Methodology, Writing – original draft, Writing – review & editing

  Affiliations Experimental Oncology Group, Tumor Biology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain

  https://orcid.org/0000-0002-0835-7069

  ⨯
• Ana Fernández-Rodríguez ,

  Contributed equally to this work with: Laura de-la-Puente-Ovejero, Ana Fernández-Rodríguez

  Roles Data curation, Formal analysis, Methodology, Writing – review & editing

  Affiliations Experimental Oncology Group, Tumor Biology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain

  https://orcid.org/0000-0001-5486-6844

  ⨯
• Sarah Francoz,

  Roles Data curation, Formal analysis, Methodology

  Affiliation Experimental Oncology Group, Tumor Biology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain

  ⨯
• Gonzalo Aizpurua,

  Roles Methodology, Writing – review & editing

  Affiliation Experimental Oncology Group, Tumor Biology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain

  ⨯
• Lucía Lomba-Riego,

  Roles Methodology

  Affiliation Experimental Oncology Group, Tumor Biology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain

  ⨯
• Matthias Drosten,

  Roles Resources

  Affiliations Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain, RAS Signalling and Lung Cancer Group, Molecular Mechanisms of Cancer Program, Centro de Investigación del Cáncer, Consejo Superior de Investigaciones Científicas-Universidad de Salamanca, Salamanca, Spain

  ⨯
• Carmen Guerra,

  Roles Funding acquisition, Resources

  Affiliations Experimental Oncology Group, Tumor Biology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain

  ⨯
• Mónica Musteanu ,

  Roles Conceptualization, Funding acquisition, Project administration, Supervision, Writing – review & editing

  * E-mail: sgarciaa@cnio.es (SG-A); mbarbacid@cnio.es (MB); mmustean@ucm.es (MM)

  Affiliations Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain, Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, Universidad Complutense de Madrid, Madrid, Spain, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain

  https://orcid.org/0000-0002-1753-3765

  ⨯
• Mariano Barbacid ,

  Roles Conceptualization, Funding acquisition, Project administration, Writing – review & editing

  * E-mail: sgarciaa@cnio.es (SG-A); mbarbacid@cnio.es (MB); mmustean@ucm.es (MM)

  Affiliations Experimental Oncology Group, Tumor Biology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain

  ⨯
• Sara García-Alonso

  Roles Conceptualization, Data curation, Formal analysis, Methodology, Project administration, Supervision, Writing – original draft, Writing – review & editing

  * E-mail: sgarciaa@cnio.es (SG-A); mbarbacid@cnio.es (MB); mmustean@ucm.es (MM)

  Affiliations Experimental Oncology Group, Tumor Biology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain

  https://orcid.org/0000-0002-0561-4146

  ⨯